Supplementary Materials

The PDF file includes:

  • Fig. S1. Immunoblot validation of response to ALK inhibition in neuroblastoma cells.
  • Fig. S2. RTK inhibition effects on three neuroblastoma cell lines.
  • Fig. S3. Cell cycle analysis and apoptosis analyses upon treatment with ALK inhibitors.
  • Fig. S4. Phosphoproteomic analysis after ALK inhibition in different neuroblastoma cell lines.
  • Fig. S5. Identification of 74 proteins with decreased phosphorylation in the CLB-BAR neuroblastoma cell line.
  • Fig. S6. ALK RNA-seq expression analysis early (1 hour) after ALK inhibition.
  • Fig. S7. RNA-seq gene expression analysis 24 hours after ALK inhibition in different neuroblastoma cell lines.
  • Fig. S8. Changes in expression of genes encoding TRKs upon treatment with ALK inhibitors in different neuroblastoma cell lines.
  • Fig. S9. Effect of ALK inhibition on RET phosphorylation and expression.
  • Fig. S10. Integrative analysis of ALK-induced phosphorylation signaling and transcriptional response.
  • Fig. S11. Kaplan-Meier event-free survival curves of 498 patients with neuroblastoma from the SEQC cohort.
  • Fig. S12. Phosphatase treatment of ETV3 and DUSP4.
  • Legends for Data files S1 to S6

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data File S1 (Microsoft Excel format). Phosphoproteomic responses 1 hour after ALK TKI treatment.
  • Data File S2 (Microsoft Excel format). Reactome GSEA on genes encoding differentially phosphorylated proteins.
  • Data File S3 (Microsoft Excel format). Expression responses 24 hours after ALK TKI treatment.
  • Data File S4 (Microsoft Excel format). Transcription factor GSEA results on 764 differentially expressed genes in the CLB-BAR cell line.
  • Data File S5 (Microsoft Excel format). Transcription factor nearest-neighborhood analysis results in CLB-BAR.
  • Data File S6 (Microsoft Excel format). Cell Signaling Technology Phosphoscan raw data.